russia covid-19 vaccine

Russia Emerges as The First Nation to Complete Human Trials of COVID-19 Vaccine

With the increasing number of Coronavirus cases and fatalities, Russia emerges as the first nation to successfully complete the clinical trials of its vaccine across the globe. The trials were conducted at the Sechenov University.

Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, stated, “Sechenov University has successfully completed tests on volunteers of the world’s first vaccine against Coronavirus.”

He highlighted that the clinical trials of the vaccine started last month. Also, Gamalei Institute of Epidemiology and Microbiology in Russia has produced the vaccine.

“The data obtained by the Gamalei National Research Center for Epidemiology and Microbiology proves that volunteers of the first and second groups are forming an immune response after injections of the vaccine against the coronavirus,” an earlier statement of the Russian Defence Ministry said.

The safety of this vaccine in correspondence with the safety of other medicines was confirmed by Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases at Sechenov University.

With this vaccine, Russia has emerged as the first nation to complete human clinical trials for Coronavirus. However, there is no update about this vaccine entering the commercial production stage.

As per the data of the World Health Organisation (WHO), more than 20 vaccines are under key trials at present.

According to the current statistics, USA accounts for the world’s highest number of COVID-19 patients and the fatalities while Brazil is at the second place.

Daniel is our UK-based freelance Editor. As part of our quest towards credible news, Doctor's Clinic Blog India affiliates with individuals from other parts of the world to provide an in-depth focus on essential topics. Daniel received his degree from the University of Sheffield, and since then, worked to multiple sites as a freelance contributor and editor.

Leave a reply